Change in eGFR levels between baseline and year 3 depending on LA positivity.

<p>(A) Change in eGFR in LA-positive patients. Patients given antiplatelet therapy had an improvement in eGFR from baseline to year 3 compared to those not given therapy (p = 0.04). The level of eGFR at year 3 was significantly higher in LA-positive patients receiving antiplatelet therapy (p = 0.04). (B) Change in eGFR in LA-negative patients. No improvement was seen. eGFR, estimated glomerular filtration rate; LA, lupus anticoagulant. *, p = 0.04.</p

Baseline clinical and renal pathological features of antiphospholipid antibody-positive LN patients with or without antiplatelet therapy.

<p>Baseline clinical and renal pathological features of antiphospholipid antibody-positive LN patients with or without antiplatelet therapy.</p

Effects of antiplatelet therapy on cumulative complete response rates or relapse-free rates.

<p>Cumulative complete renal response rate (A) and relapse-free rate (B) for 3 years after induction therapy depending on the antiplatelet treatment received. A full line indicates patients who received antiplatelet therapy and a dotted line indicates those who did not. There was no difference between these groups in terms of CR rate (p = 0.4) and relapse-free rate (p = 0.5). CR, Complete renal response.</p

Baseline clinical and renal pathological features according to LA status.

<p>Baseline clinical and renal pathological features according to LA status.</p

Change in eGFR levels over 3 years.

<p>There was no difference in eGFR level between patients with antiplatelet therapy and those without at any observational points. eGFR, estimated glomerular filtration rate.</p

Adverse events during 3 years.

<p>Adverse events during 3 years.</p

Relapse free rate for 3 years after CR achievement.

<p>There was no significant difference among the four treatment groups. CR, Complete renal response; IVCY, intravenous cyclophosphamide; ELNT, Euro-Lupus Nephritis Trial; TAC, Tacrolimus; MMF, mycophenolate mofetil.</p

Relapse free rate for 3 years from study enrollment.

<p>There was no significant difference among the four treatment groups. CR, Complete renal response; IVCY, intravenous cyclophosphamide; ELNT, Euro-Lupus Nephritis Trial; TAC, Tacrolimus; MMF, mycophenolate mofetil.</p

Baseline clinical and renal pathological features of lupus nephritis patients with immunosuppressive therapy.

<p>Baseline clinical and renal pathological features of lupus nephritis patients with immunosuppressive therapy.</p

Multivariate analysis for predictors of patients with increasing SDI over 3 years.

<p>Multivariate analysis for predictors of patients with increasing SDI over 3 years.</p